EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Comprehensive Technology Platform for the Rapid Discovery of Peptide Inhibitors against SARS-CoV-2 Pseudovirus Infection

Marten Beeg iD, Sara Baroni iD, Arianna Piotti, Alessia Porta, Ada De Luigi iD, Alfredo Cagnotto iD, Marco Gobbi iD, Luisa Diomede iD, Mario Salmona iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241512146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Marten Beeg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milan, Italy. Hauptthemen laut MEDLINE: COVID-19, RNA Viruses. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo Beneficienza Intesa Sanpaolo, European Union, EU funding within the NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We developed and validated a technology platform for designing and testing peptides inhibiting the infectivity of SARS-CoV-2 spike protein-based pseudoviruses. This platform integrates target evaluation, in silico inhibitor design, peptide synthesis, and efficacy screening. We generated a cyclic peptide library derived from the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and the angiotensin-converting enzyme 2 (ACE2) receptor. The cell-free validation process by ELISA competition assays and Surface Plasmon Resonance (SPR) studies revealed that the cyclic peptide c9_05, but not its linear form, binds well to ACE2. Moreover, it effectively inhibited the transduction in HEK293, stably expressing the human ACE2 receptor of pseudovirus particles displaying the SARS-CoV-2 spike in the Wuhan or UK variants. However, the inhibitory efficacy of c9_05 was negligible against the Omicron variant, and it failed to impede the entry of pseudoviruses carrying the B.1.351 (South African) spike. These variants contain three or more mutations known to increase affinity to ACE2. This suggests further refinement is needed for potential SARS-CoV-2 inhibition. Our study hints at a promising approach to develop inhibitors targeting viral infectivity receptors, including SARS-CoV-2’s. This platform also promises swift identification and evaluation of inhibitors for other emergent viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19RNA VirusesHumansSARS-CoV-2Angiotensin-Converting Enzyme 2HEK293 CellsPeptidesPeptides, CyclicPeptide LibraryTechnologyProtein BindingSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

COVID-19ELISA and SPR assaysSARS-CoV-2drug discovery pipelinemacrocyclic peptidespeptide inhibitorspseudovirus entry assay

Substanzen

Angiotensin-Converting Enzyme 2PeptidesPeptides, CyclicPeptide Libraryspike protein, SARS-CoV-2Spike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milan, Italy.

ORCID-Profile: Marten Beeg, Sara Baroni, Ada De Luigi, Alfredo Cagnotto, Marco Gobbi, Luisa Diomede, Mario Salmona

Förderung

  • Fondo Beneficienza Intesa Sanpaolo
  • European Union
  • EU funding within the NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases

Zitieren

APA

Beeg, M., Baroni, S., Piotti, A., Porta, A., De Luigi, A., Cagnotto, A., Gobbi, M., Diomede, L., & Salmona, M. (2023). A Comprehensive Technology Platform for the Rapid Discovery of Peptide Inhibitors against SARS-CoV-2 Pseudovirus Infection. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512146

Vancouver

Beeg M, Baroni S, Piotti A, Porta A, De Luigi A, Cagnotto A, et al. A Comprehensive Technology Platform for the Rapid Discovery of Peptide Inhibitors against SARS-CoV-2 Pseudovirus Infection. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512146

BibTeX
@article{Beeg2023,
  author = {Beeg, Marten and Baroni, Sara and Piotti, Arianna and Porta, Alessia and De Luigi, Ada and Cagnotto, Alfredo and Gobbi, Marco and Diomede, Luisa and Salmona, Mario},
  title = {A Comprehensive Technology Platform for the Rapid Discovery of Peptide Inhibitors against SARS-CoV-2 Pseudovirus Infection},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241512146}
}
Kostenlos starten →